Lykos to cut 75% of staff after FDA rejection of MDMA-based therapy
Lykos and its founder, Rick Doblin, have for years tried to persuade regulators and the pharmaceutical industry at large that psychedelic drugs should be used in the treatment of certain mental health conditions.
“After 38 plus years of work, I’m profoundly saddened by the FDA decision around this critically needed therapy, but am heartened that Lykos will still move forward continuing clinical research that addresses the FDA’s questions,” Doblin said… has left his position on the Lykos’ board.
Original Article (The Conversation & Oregon Public Policy Center):
Lykos to cut 75% of staff after FDA rejection of MDMA-based therapy
Artwork Fair Use: amousey with minor modifications from the pd work file
Recent Comments